Navigation Links
Rheumatoid Arthritis Market Forecast
Date:9/20/2011

NEW YORK, Sept. 20, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Rheumatoid Arthritis Market Forecast

http://www.reportlinker.com/p0360301/Rheumatoid-Arthritis-Market-Forecast.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology

The launch of novel oral drugs and reformulations of current brands are expected to fuel growth across the seven major markets, rising from $12bn in 2010 to $18bn by 2020. TNF inhibitors will remain dominant market players, but the growing enthusiasm for non-TNF biologics at earlier lines of therapy is predicted to continue over the next decade and serves as an additional growth driver.Gain insight into the RA competitive landscape and assess commercial opportunity using 10 year patient-based forecasts with clear methodology.Access current and future patient-numbers and expand knowledge on potential future events that may impact these.Evaluate existing and potential future brand dynamics by line of therapy; from first- through to fourth-line and beyond.Enhance understanding of future product potential, with key opinion leader views of late stage kinase inhibitors, such as tofacitinib and FosD.Gauge the anticipated impact of reformulations on patient switching and the subsequent effect on total brands sales.With two novel kinase inhibitors forecast to launch for rheumatoid arthritis and key brand reformulations set to enter the market over the next decade, Datamonitor's patient-based forecast shows that the market will grow to reach $18bn in 2020.Despite news of deaths in a Phase III trial of Pfizer's tofacitinib, physicians remain upbeat on this potential game-changer, stating that wh
'/>"/>

SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. New Risk Gene for Rheumatoid Arthritis and Lupus Opens Door to More Effective Treatments
2. Trubion Announces Preliminary Analysis of Phase IIb Results With TRU-015 in Rheumatoid Arthritis
3. Targeted Genetics Reports on Recombinant DNA Advisory Committee (RAC) Review of its Phase 1/2 Trial of tgAAC94 for Rheumatoid Arthritis
4. CIMZIA(R) (certolizumab pegol), Significantly Reduces Structural Damage and Rheumatoid Arthritis Signs & Symptoms for Up to One Year
5. Two Pivotal Phase III Studies for Roches ACTEMRA(TM) (tocilizumab) Demonstrate Significant Improvement in Rheumatoid Arthritis Symptoms
6. Trubion Pharmaceuticals Announces Presentation of Positive Data From Phase IIb and Re-treatment Studies With TRU-015 in Patients With Rheumatoid Arthritis
7. Five-Year Data Demonstrate Long-Term Efficacy and Safety with ORENCIA(R) (abatacept) in Adults with Rheumatoid Arthritis Who had an Inadequate Response to Methotrexate
8. Lexicon Files Investigational New Drug Application for LX2931 as a Potential Treatment for Rheumatoid Arthritis
9. Post-Hoc Data Show Daily Activity Participation, Independence and Sleep Quality Improved in Adults with Moderate to Severe Rheumatoid Arthritis After Treatment with ORENCIA(R) (Abatacept)
10. Roche Submits Application for FDA Approval of ACTEMRA(R) for the Treatment of Rheumatoid Arthritis
11. MedImmune Initiates First Clinical Trial of Monoclonal Antibody Targeting GM-CSFR in Patients with Rheumatoid Arthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... Jan. 23, 2015 A lot of discussion in the ... treating  certain illnesses, injuries, or conditions. As medical science advances, ... methods with ones that they consider to be more cutting ... not one textbook method of treatment that stands out as ...
(Date:1/23/2015)...  The Partnership to Fight Chronic Disease (PFCD) released a public opinion ... a new study analyzing the impact of increased cost sharing on ... working to educate policy makers and the public on the costs ... on how the Iowa healthcare exchange could ...
(Date:1/23/2015)... BETHESDA, Md. , Jan. 23, 2015  Northwest Biotherapeutics, Inc. ... developing DCVax® personalized immune therapies for operable and inoperable solid ... will present at the 7 th Annual Phacilitate Immunotherapy ... NW Bio,s presentation at Phacilitate will take place on January ...
Breaking Medicine Technology:No One-Size-Fits-All Remedy for Hernia Correction 2New research shows Iowa health exchange would benefit from improvements 2New research shows Iowa health exchange would benefit from improvements 3NW Bio To Present At The 7th Annual Phacilitate Immunotherapy Forum 2NW Bio To Present At The 7th Annual Phacilitate Immunotherapy Forum 3
... filed suit today against Johnson & Johnson, Inc. and DePuy ... of the DePuy ASR XL Acetabular Hip Replacement System that ... of John David Hart in Fort Worth, Texas, is the ... United States District Court for the Eastern District of Texas ...
... (Becton, Dickinson and Company) (NYSE: BDX ), ... of its acquisition of Accuri Cytometers, Inc., an Ann ... cytometers for researchers. The acquisition expands BD,s ... and helps expand the use of flow cytometry technology ...
Cached Medicine Technology:DePuy Recalled Hip Device Lawsuit Filed in East Texas 2BD Completes Acquisition of Accuri Cytometers, Inc. 2
(Date:1/22/2015)... 2015 Gabe’s Chemo Duck Program is pleased to ... app ever created for kids with cancer. The Chemo Duck App, ... is filled with enjoyable games to help children of all ages ... app helps to keep kids entertained, educated and at ease while ...
(Date:1/22/2015)... January 22, 2015 Blue Cross and Blue ... who exemplify what it means to “Live Fearless.” ... people to share their stories about how they or someone ... inspired others by living in the moment. By telling these ...
(Date:1/22/2015)... New York, New York (PRWEB) January 22, 2015 ... filed after Fresenius Medical Care recalled its GranuFlo ... the federal multidistrict litigation underway in U.S. District Court, ... an Order dated January 20th, the Court has remanded ...
(Date:1/22/2015)... York, NY (PRWEB) January 22, 2015 ... College of Sports Medicine flagship journal Medicine & ... with L-Citrulline before exercise may help reduce gastrointestinal ... exercise. 1 , Participants in the double-blind, ...
(Date:1/22/2015)... DC (PRWEB) January 22, 2015 Payday ... in vulnerable communities and cause financial distress to the ... by analysts at Howard University’s Center on Race and ... dollars in economic activity, payday loans at the same ...
Breaking Medicine News(10 mins):Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 2Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 3Health News:Blue Cross and Blue Shield of Minnesota to Showcase “Faces of Fearless” 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 4Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3Health News:Howard University Spotlights the Economic Impact of Payday Lending in Southern States 2
... of vegetables and fruits could be worse than abusing alcohol ... ,It has been estimated that the minimum recommended daily ... vegetables at least. ,According to the 2005 ... accounted for a disability adjusted life years (DALY) rating of ...
... Researchers have confirmed that their studies on bacteria that ... widespread and persistent ear infections// that irritate kids, which ... is pointless. ,Otitis media, a condition of ... to visit doctor and or antibiotic prescriptions in the ...
... science and microbiology and molecular genetics, and his colleagues from ... the ability and potential for growing flu virus. , ... production of new human flu vaccines which is cheaper and ... He identified the new cell line while working on the ...
... are taking part in an initiative to gauge if ... people who have suffered a stroke recently//. The MíTICO ... Isquemic Ictus. ,The study included patients from different ... to three months previously. By means of periodical controls, ...
... is working on four vaccines, including those for treating ... currently working on four vaccines for anthrax, dengue, Japanese ... anthrax vaccine have been completed, which is ready for ... told reporters here today., ,The company would also ...
... wireless device that measures the acidity of stomach contents ... of the nose pain and throat discomfort// associated with ... reflux disease. ,However, while the new technology ... was better for diagnosing or managing these patients, said ...
Cached Medicine News:Health News:‘Biofilms’-Clumped Bacterial Slime Cause Ear Infecti 2Health News:New Cell Lines Cuts Down the Cost and Time in the Production of Flu Vaccine 2Health News:New Reflux Disease Technology More Comfortable, Not More Effective 2Health News:New Reflux Disease Technology More Comfortable, Not More Effective 3
The CdTOX A OIA gets the results you need without specimen extraction or instrumentation. Results are available in minutes vs hours or days for EIA or other methods. The combination of performance, ...
... for Botox therapy and nerve block ... injectable needle has a precisely machined ... with an attached 61-cm (24-in) lead ... insertion. Single patient use only. A ...
... Back Relief Apron has standard ... the weight from the shoulders ... aid of a 6" wide ... strap keeps apron snug. Belts ...
Shielding's Standard Coat Apron with open back allows for freedom of movement, maximum flexibility and increased comfort....
Medicine Products: